Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis

Oncology Reports

Volumn 17, Issue 6, 2007, Pages 1383-1389

  Hu, Li De ^a   Zou, Hua Fei ^a   Zhan, Shu Xuan ^a   Cao, Kai Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Biphasic patter; Breast cancer; Immunohistochemistry; Lymph node metastasis; RhoGDI2

Indexed keywords

ARHGDIB PROTEIN, HUMAN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; CHEMISTRY; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 34548052025     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.6.1383     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer Statistics, 2005. CA Cancer J Clin 55: 10-30, 2005. (Pubitemid 40310185)
2. Welch DR and Rinker-Schaeffer CW: What defines a useful marker of metastasis in human cancer? J Natl Cancer Inst 91: 1351-1353, 1999. (Pubitemid 29399993)
3. Yoshida BA, Sokoloff MM, Welch DR and Rinker-Schaeffer CW: Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 92: 1717-1730, 2000.
4. Sahai E: Mechanisms of cancer cell invasion. Curr Opin Genet Dev 15: 87-96, 2005.
5. Van Aelst L and D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev 11: 2295-2322, 1997. (Pubitemid 27408529)
6. Hall A: Rho GTPases and the actin cytoskeleton. Science 279: 509-514, 1998.
7. Schmitz AA, Govek EE, Böttner B and Van Aelst L: Rho GTPases: signaling, migration, and invasion. Exp Cell Res 261: 1-12, 2000.
8. Del Pulgar TG, Benitah SA, Valerón PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 27: 602-613, 2005.
9. Sahai E and Marshall CJ: Rho-GTPase and cancer. Nat Rev Cancer 2: 133-142, 2002.
10. Olofsson B: Rho guanine dissociation inhibitors: pivotal molecules in cellular signaling. Cell Signal 11: 545-554, 1999.
11. Dransart E, Olofsson B and Cherfils J: RhoGDIs revisited: Novel roles in Rho regulation. Traffic 6: 957-966, 2005. (Pubitemid 41472455)
12. Su LF, Knoblauch R and Garabedian MJ: Rho GTPases as modulators of the estrogen receptor transcriptional response. J Biol Chem 276: 3231-3237, 2001.
13. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of Rho GTPases and Rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9: 6432-6440, 2003. (Pubitemid 38031830)
14. Zhang YQ and Zhang BL: D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res 66: 5592-5598, 2006.
15. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RVP, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS and Greene FL: Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol 20: 3628-3636, 2002. (Pubitemid 34983222)
16. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM and Frierson HF Jr: Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10: 3800-3806, 2004. (Pubitemid 38697615)
17. Lakhani SR: The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 187: 272-278, 1999.
18. Beckmann MW, Niederacher D, Schnürch HG, Gusterson BA and Bender HG: Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 75: 429-439, 1997. (Pubitemid 27297013)
19. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR and Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992.
20. Bachmeier BE, Albini A, Vené R, Benelli R, Noonan D, Weigert C, Weiler C, Lichtinghagen R, Jochum M and Nerlich AG: Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Exp Cell Res 305: 83-98, 2005. (Pubitemid 40380656)
21. Zhang RD, Fidler IJ and Price JE: Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 11: 204-215, 1991.
22. Price JE, Polyzos A, Zhang RD and Daniels LM: Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50: 717-721, 1990. (Pubitemid 20054204)
23. Lin M and van Golen KL: Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 84: 49-60, 2004. (Pubitemid 38388860)
24. Lelias JM, Adra CN, Wulf GM, Guillemot JC, Khagad M, Caput D and Lim B: cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins. Proc Natl Acad Sci USA 90: 1479-1483, 1993. (Pubitemid 23058196)
25. Scherle P, Behrens T and Staudt LM: Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci USA 90: 7568-7572, 1993. (Pubitemid 23249991)
26. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR and Theodorescu D: RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62: 6418-6423, 2002. (Pubitemid 35364098)
27. Tapper J, Kettunen E, El-Rifai W, Seppälä M, Andersson LC and Knuutila S: Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 128: 1-6, 2001. (Pubitemid 32655473)
28. Cui JW, Li WH, Wang J, Li AL, Li HY, Wang HX, He K, Li W, Kang LH, Yu M, Shen BF, Wang GJ and Zhang XM: Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 4: 1718-1724, 2005. (Pubitemid 41749265)
29. Yanagawa T, Watanabe H, Takeuchi T, Fujimoto S, Kurihara H and Takagishi K: Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-β. Lab Invest 84: 513-522, 2004. (Pubitemid 41656479)
30. Ota T, Maeda M, Suto S and Tatsuka M: LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane. Mol Carcinog 39: 206-220, 2004. (Pubitemid 38452241)
31. Lacroix M and Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249-289, 2004. (Pubitemid 38264873)
32. Huang CL, Kohno N, Ogawa E, Adachi M, Taki T and Miyake M: Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 153: 973-983, 1998. (Pubitemid 28419050)
33. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ and Shao ZM: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88: 75-85, 2004. (Pubitemid 39524447)